Residency · Residency · Medicine Pediatrics
Cancer Survivorship: Late Effects of Childhood Cancer Treatment
Overview
Over 85% of children with cancer now survive 5+ years, creating a growing population of >500,000 childhood cancer survivors in the US. Two-thirds of survivors develop at least one chronic health condition; one-third develop a severe or life-threatening condition. Late effects result from the cancer itself, surgery, chemotherapy, and radiation therapy. Med-Peds physicians are uniquely positioned to manage the transition from pediatric oncology surveillance to adult primary care.
Late Effects by Organ System
| Organ System | Causative Treatment | Key Late Effect | Screening | Onset Latency |
|---|---|---|---|---|
| Cardiovascular | Anthracyclines (>300 mg/m2) | Dilated cardiomyopathy | Echo every 1-5 years | 5-20+ years |
| Cardiovascular | Chest radiation (>30 Gy) | CAD, valvular disease | Echo, stress test | 10-30 years |
| Endocrine | Cranial radiation (>18 Gy) | GH deficiency | IGF-1, provocative testing | 2-5 years |
| Endocrine | Neck/mantle radiation | Hypothyroidism | Annual TSH | 2-10 years |
| Gonadal | Alkylating agents | POI / azoospermia | AMH, semen analysis | Variable |
| Pulmonary | Bleomycin (>400 units) | Pulmonary fibrosis | PFTs (DLCO) | 1-10 years |
| Secondary malignancy | Chest radiation (ages 10-30) | Breast cancer | Mammography + MRI at age 25 | 8-20+ years |
| Neurocognitive | Cranial radiation (<5 years old) | IQ decline, executive dysfunction | Neuropsychological testing | Progressive |
| Musculoskeletal | Corticosteroids | Osteonecrosis (AVN) | Clinical; MRI if symptomatic | 1-5 years |
| Renal | Ifosfamide | Fanconi syndrome, CKD | Electrolytes, creatinine | 1-10 years |
Cardiovascular Late Effects
Anthracycline-Related Cardiomyopathy
Doxorubicin and daunorubicin are dose-dependently cardiotoxic. Risk increases with cumulative dose >300 mg/m2, younger age at treatment, and female sex. Mechanism: oxidative stress, mitochondrial damage, cardiomyocyte apoptosis. Presentation: dilated cardiomyopathy with reduced ejection fraction; may be subclinical for years then decompensate with physiologic stress (pregnancy, exercise, illness) Screening: echocardiogram every 1-5 years based on exposure and risk (COG Long-Term Follow-Up Guidelines) Treatment: standard heart failure therapy (ACEi/ARB, beta-blocker, diuretics); may require transplantation.
Radiation-Related Cardiac Disease
Chest/mediastinal radiation (Hodgkin lymphoma treatment) causes:; Premature coronary artery disease (10-30 years post-treatment); Valvular disease (fibrosis and calcification); Constrictive pericarditis; Conduction abnormalities; Risk increases with dose >30 Gy and concurrent anthracycline use; Screening: echocardiogram and stress testing; lower threshold for cardiac catheterization.
<image>Timeline showing onset of cardiovascular late effects after childhood cancer treatment including early subclinical changes and late clinical manifestations of cardiomyopathy, valvular disease, and coronary artery disease</image>
Secondary Malignancies
Risk Factors
Radiation therapy is the strongest risk factor (especially for solid tumors in the radiation field) Alkylating agents (cyclophosphamide, ifosfamide): increased risk of secondary leukemia (AML/MDS) Topoisomerase II inhibitors (etoposide): acute myeloid leukemia, typically within 2-3 years. Genetic predisposition syndromes (Li-Fraumeni, NF1, retinoblastoma gene carriers)
Common Secondary Malignancies
Breast cancer: females irradiated to chest between ages 10-30 have risk approaching BRCA carriers; annual mammography + breast MRI starting age 25 or 8 years post-radiation (whichever is later) Thyroid cancer: after neck/mantle radiation; annual thyroid exam, low threshold for ultrasound. Skin cancer: basal cell carcinoma in radiation fields; annual dermatologic exam. Sarcoma: bone and soft tissue sarcomas in radiation fields (10-20 year latency) Secondary leukemia/MDS: typically 2-10 years post-treatment; poor prognosis. CNS tumors: meningiomas after cranial radiation (very long latency, 20+ years)
Endocrine Late Effects
Growth and Puberty
Cranial radiation (>18 Gy) causes growth hormone deficiency — the most common endocrine late effect. GH deficiency: short stature, increased fat mass, decreased lean mass, metabolic syndrome. Screen with IGF-1 and provocative GH testing; treat with recombinant GH if deficient. Precocious puberty: may follow low-dose cranial radiation (<18 Gy) leading to premature GnRH activation. Spinal radiation: disproportionate short trunk; sitting height affected more than standing height.
Thyroid Dysfunction
Hypothyroidism: most common endocrine effect of neck/mantle radiation (40-60% incidence) Annual TSH screening; treat with levothyroxine. Hyperthyroidism: less common (Graves-like disease) Thyroid nodules and cancer: see secondary malignancies above.
Gonadal Dysfunction
Males: alkylating agents damage germinal epithelium (oligospermia/azoospermia) while Leydig cells are more resistant; may have normal testosterone with impaired fertility. Females: alkylating agents cause premature ovarian insufficiency (POI); ovarian reserve declines with dose; anti-Mullerian hormone (AMH) is the best marker of ovarian reserve. Pelvic/gonadal radiation: direct gonadal damage. Fertility preservation: sperm banking pre-treatment in pubertal males; oocyte/embryo cryopreservation or ovarian tissue cryopreservation in females.
Metabolic Syndrome
Cranial radiation survivors have increased risk of obesity, insulin resistance, dyslipidemia. Contribution of GH deficiency, reduced physical activity, hypothalamic damage. Screen with fasting glucose, lipids, blood pressure annually.
<image>Diagram of endocrine organs affected by cancer treatment showing radiation dose thresholds for hypothalamic-pituitary axis, thyroid, and gonadal damage with associated screening recommendations</image>
Neurocognitive Late Effects
Risk Factors
Cranial radiation (especially <5 years of age at treatment); Intrathecal and high-dose systemic methotrexate; Brain surgery; Younger age at treatment = greater impact.
Manifestations
Decline in IQ (average 10-20 point reduction after cranial radiation) Processing speed, attention, working memory, and executive function most affected. Academic difficulties, reduced educational attainment, lower employment rates. Increased rates of depression and anxiety. Neurocognitive decline may be progressive over years after treatment.
Management
Baseline and serial neuropsychological testing; Educational accommodations (IEPs, 504 plans); Cognitive rehabilitation programs; Methylphenidate or other stimulants for attention deficits (evidence supports use in survivors).
Pulmonary Late Effects
Bleomycin: pulmonary fibrosis; risk increases with cumulative dose >400 units, concurrent radiation, renal impairment. BCNU (carmustine): dose-dependent pulmonary fibrosis. Chest radiation: pneumonitis acutely; fibrosis chronically; restrictive lung disease. Screening: PFTs (DLCO, spirometry) at baseline and as indicated. Counsel against smoking; caution with supplemental oxygen during surgery (bleomycin-related lung injury risk)
Musculoskeletal Late Effects
Osteonecrosis (avascular necrosis): most common with corticosteroids (especially dexamethasone) and in adolescents; hip, knee most affected. Osteoporosis: corticosteroids, methotrexate, radiation, hypogonadism, GH deficiency. Limb length discrepancy: radiation to growing bones. DEXA screening for at-risk survivors; weight-bearing exercise, calcium, vitamin D supplementation.
Renal and Urologic Late Effects
Ifosfamide: Fanconi syndrome (proximal tubular dysfunction), CKD. Cisplatin: dose-dependent nephrotoxicity, electrolyte wasting (magnesium) Nephrectomy (Wilms tumor): monitor remaining kidney function, blood pressure. Annual electrolytes, creatinine, urinalysis; avoid nephrotoxic medications.
Psychosocial and Quality of Life
Post-traumatic stress in both survivors and parents; Body image concerns (alopecia, surgical scars, limb loss, short stature); Social isolation, peer relationship difficulties; Reduced health-related quality of life compared to age-matched peers; Higher rates of anxiety, depression, and suicidal ideation; Employment and insurance discrimination.
Transition to Adult Survivorship Care
COG Long-Term Follow-Up (LTFU) Guidelines
Risk-based screening recommendations based on specific exposures (available at survivorshipguidelines.org) Individualized "survivorship care plan" summarizing diagnosis, treatment exposures, and recommended surveillance. Should be provided to every survivor and their adult primary care provider.
Models of Survivorship Care
Shared care: pediatric oncology and adult primary care collaborate. Risk-stratified: low-risk survivors managed by PCP with guidelines; high-risk in dedicated survivorship clinics. Dedicated survivorship clinics: multidisciplinary teams (oncology, cardiology, endocrinology, neuropsychology, social work) Med-Peds physicians are ideal providers for survivorship care given training in both pediatric and adult medicine.
<image>Survivorship care plan template showing treatment summary with chemotherapy agents and cumulative doses, radiation fields, and a risk-based screening schedule organized by organ system</image>
Clinical Pearls
Every childhood cancer survivor needs a detailed treatment summary including specific agents and cumulative doses — this drives all screening recommendations. Anthracycline cardiomyopathy can present decades after treatment; pregnancy is a common physiologic trigger in female survivors. Female survivors who received chest radiation between ages 10-30 should undergo breast cancer screening like high-risk patients (annual MRI + mammography) — standard population screening is insufficient. Hearing loss from cisplatin is irreversible and progressive; annual audiology is essential. Childhood cancer survivors have a 15x higher risk of developing a subsequent malignancy compared to the general population. Survivors receiving cranial radiation before age 5 are at highest risk for neurocognitive deficits — refer early for neuropsychological evaluation and educational support. Screen for depression and anxiety at every visit — mental health is the most underaddressed survivorship issue.
References
- Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 6.0. 2023.
- Armstrong GT, Chen Y, Yasui Y, et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med. 2016;374(9):833-842.
- Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic Health Conditions in Adult Survivors of Childhood Cancer. N Engl J Med. 2006;355(15):1572-1582.
- Hudson MM, Ness KK, Gurney JG, et al. Clinical Ascertainment of Health Outcomes among Adults Treated for Childhood Cancer. JAMA. 2013;309(22):2371-2381.
